| Strong evidence of benefit*: |
| Moderate-to-severe allergic asthma (patients greater than 6 years of age) |
| Chronic spontaneous urticaria (patients greater than 12 years of age) |
| Chronic rhinosinusitis with nasal polyposis (patients greater than 18 years of age) |
| Good evidence of benefit: |
| Chronic inducible urticaria |
| Allergic rhinitis |
| Food allergy |
| Protection from systemic allergic reactions during aeroallergen, venom, or food immunotherapy |
| Protection from systemic allergic reactions during drug desensitization |
| Viral-induced asthma exacerbations |
| Some evidence of benefit: |
| Nonallergic asthma |
| Mast cell activation disorders |
| Atopic dermatitis |
